Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostate Adenocarcinoma × flibanserin × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostate Adenocarcinoma 1 Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5 luprolide acetate gel depot 3 Radiotherapy 3 Radiosurgery 3 Radiation 3 Leuprolide 3 Goserelin 3 relugolix 2 gallium 68 PSMA-11 2 enzalutamide 2 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2 Triptorelin Pamoate 2 radium Ra 223 dichloride 1 niraparib 1 histrelin 1 fluciclovine F-18 1 flibanserin 1 entinostat 1 darolutamide 1 bicalutamide 1 atezolizumab 1 apalutamide 1 abiraterone 1 X-Rays 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Specimen Handling 1 Salicylic Acid 1 Receptors, Bombesin 1 Radiotherapy, Image-Guided 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04743934 2025-05-04

RAD 2003

University of Alabama at Birmingham

Phase 2 Active not recruiting

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡